NDAORALCAPSULEPriority Review
Approved
Apr 2017
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
5/8 — Partial
Priority Review
RYDAPT (rydapt) by Novartis is receptor tyrosine kinase inhibitors [moa]. Approved for kinase inhibitor [epc]. First approved in 2017.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RYDAPT (midostaurin) is an oral small-molecule receptor tyrosine kinase inhibitor developed by Novartis and approved by the FDA on April 28, 2017. It functions as a multi-targeted kinase inhibitor that blocks multiple receptor tyrosine kinases involved in cancer cell proliferation and survival. RYDAPT is indicated for kinase inhibitor-responsive malignancies and represents a key option in the targeted oncology treatment landscape, competing directly with other kinase inhibitors in the same therapeutic class.
$0.0BPart D
4.6 years to LOEMechanism of Action
Receptor Tyrosine Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on RYDAPT at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.